UNITED STATES SECURITIES AND EXCHANGE COMMISSION  WASHINGTON, D.C. 20549  FORM 10-QSB/A  [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2004  [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from __________________ to __________________  Commission File Number 0-23957   MEDITECNIC, INC. (Exact Name of small business issuer as specified in its charter)  Nevada 87-0430532 (State or other Jurisdiction of I.R.S. Employer Identi- Incorporation or Organization fication No.)  24351 Pasto Road, #B, Dana Point, California 92629 (Address of Principal Executive Offices) (Zip Code)  (949) 489-2400 (Issuer's Telephone Number, including Area Code)  Indicate by check mark whether the Registrant (i) has filed all reports required to be filed by Section 13, or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (of for such shorter period that the Registrant was required to file such reports) and (ii) has been subject to such filing requirements for the past 90 days.  YesNo X Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. YesNo __X__ Indicate the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date.  Common Stock, par value  $.001 7,527,485 Title of Class Number of Shares outstanding at October 6, 2008 Transitional Small Business Format     Yes     No X      MEDITECNIC, INC. (A DEVELOPMENT STAGE COMPANY) BALANCE SHEET AS OF SEPTEMBER 30, 2004 AND DECEMBER 31, 2003  September 30 December 31 ASSETS 2004 2003  Current Assets Cash and Cash Equivalents $ 16,356 $ 161,658 Interest Receivable 15,107 38,741 Accounts Receivable 262 -- Inventory 103,740 -- Marketable Securities 22,855 96,030 Total Current Assets $ 158,320 $ 296,429  Fixed Assets Vehicles 15,774 15,774 Office Furniture 17,871 17,871 Office Equipment 56,340 56,340 Data Processing Equipment 40,402 20,681 Equipment Installation 43,362 49,044 Organization Costs 23,449 23,449 197,198 183,159 Accumulated Depreciation (144,510) (130,608) Total Fixed Assets 52,688 52,551  Other Assets Patents 637,260 637,260 Research and Development -- 62,120 Refundable Deposits 234,066 241,121 Total Other Assets 871,326 940,501  Total Assets $ 1,082,334 $ 1,289,481  LIABILIITES AND STOCKHOLDERS EQUITY Current Liabilities Accounts Payable 153,586 198,796 Accrued Payroll Taxes -- 18,114 Loans from Shareholders 1,105,103 719,472 Total Current Liabilities 1,258,689 936,382  Stockholders Equity Preferred Stock (1,000 shares issued and outstanding) 1 1 Capital Stock (7,527,485 issued and outstanding) 7,528 7,528 Additional Paid In Capital 3,495,072 3,495,072 Accumulated Deficit During the Development Stage (3,696,666) (3,165,980) Accumulated Other Comprehensive Income 17,711 16,477 (176,355) 353,099  Total Liabilities and Stockholders Equity $ 1,082,334 $ 1,289,481     See accompanying Notes to Financial Statements.


MEDITECNIC, INC. (A DEVELOPMENT STAGE COMPANY) STATEMENTS OF OPERATIONS CUMULATIVE FOR THE SIX FOR THE THREE FROM MONTHS ENDED MONTHS ENDED MARCH 24, 1998 SEPTEMBER 30 SEPTEMBER 30 SEPTEMBER 30 SEPTEMBER 30 TO Income 2004 2003 2004 2003 SEPTEMBER 30, 2004 Sales Turnover $ -- $ -- $ -- $ -- $ 258,814 Research and Development -- -- -- -- 357,332 Realization of Patents -- -- -- -- 90,734 Other Revenue 51 7,429 -- 2,476 14,081 Total Income 51 7,429 -- 2,476 720,961  Operating Expenses General and Administrative 10,500 35,470 10,594 22,402 248,612 Bank Charges 913 5,853 435 4,263 48,365 Audit Fees 38,260 8,020 2,500 1,120 27,975 Marketing and Advertising 3,284 3,303 1,467 1,101 10,413 Other Financial Charges 1,041 24 -- (28) 55,877 Legal and Honoraries Fees 47,130 5,092 2,891 5,092 26,096 Research and Development -- 57,042 -- 2,347 1,049,844 Translation Fees -- -- -- -- 3,619 Patent Fees 76,388 87,026 45,181 22,838 476,293 Travel 7,813 21,669 7,286 7,243 94,704 Depreciation 13,902 12,162 4,054 4,054 56,640 Amortization 58,513 127,032 29,526 42,344 371,009 Staff Research 134,306 78,100 57,885 14,923 721,092 Office Expense 1,540 10,854 1,655 3,618 36,428 Vehicle Expense 4,433 -- -- -- -- Entertainment -- -- 4,314 -- 12,943 Small Materials and Supplies -- -- -- -- 69,490 Postage and Delivery 311 189 192 63 1,216 Insurance 1,716 306 680 102 10,073 Promotions and Seminars 6,953 17,883 2,490 5,961 73,476 Telephone 6,123 2,160 315 720 7,612 Office Rent 69,553 19,197 23,145 6,399 118,034 Utilities -- -- -- -- 318 Repairs and Maintenance -- 224 109 74 1,637 Payroll Taxes 28,921 22,815 7,899 7,605 54,119 Total Operating Expenses 511,600 514,421 202,618 152,241 3,575,885  Net Operating Income (Loss) (511,549) (389,833) (200,142) (112,341) (2,857,453)  Other Income (Expense) Interest Income -- 1,833 -- (208) 38,607 Interest Expense (1,788) (1,653) -- (551) (14,108) Insurance Indemnities -- -- -- -- 10,568 Other Taxes (17,350) (4,662) (520) (1,880) (15,335) Total Other Income (Expense) (19,138) (4,482) (520) (2,639) 19,732  Net Income (Loss) $ (530,687) $ (394,315) $ (200,662) $ (114,980) $ (2,837,721)  Other Comprehensive Income (Loss) Gains (Losses) on Exchange Rates (14,320) (9,989) (4,804) (4,804) (30,621) Change in Value of Life Insurance -- -- -- -- 12,744 Gain (Loss) in Marketable Securities 15,554 (15,941) 7,278 (8,991) 36,106 Net Comprehensive Income (Loss) 1,234 (25,930) 2,474 (13,795) 18,229  Net Income (Loss) per share $ (0.0705) $ (0.0524) $ (0.0267) $ (0.0153) $ (0.3770)  Net Operating Income (Loss) (51) 7,429 -- 2,476 720,961  Other Income (Expense) Interest Income -- 20,456 -- 7,860 36,774 Interest Expense -- (4,772) -- (9) (7,301) Other Taxes (4,662) (4,772) -- (9) (4,662) Total Other Income (Expense) (4,662) 10,912 -- 7,842 24,811  Net Income (Loss) $ (4,611) $ 18,341 $ -- $ 10,318 $ 745,772  Other Comprehensive Income (Loss) Gain in Marketable Securities (35,700) 19,693 (21,980) 830 38,304 Exchange Adjustment (5,537) -- 112 -- 31,998 Net Other Comprehensive Income (Loss) (41,237) 19,693 (21,868) 830 70,302  Net Income (Loss) per share $ (0.0006) $ (0.0024) $ -- $ (0.0014) $ (0.0991)   See accompanying Notes to Financial Statements      MEDITECNIC, INC. (A DEVELOPMENT STAGE COMPANY) STATEMENT OF CASH FLOWS CUMULATIVE FOR THE NINE FOR THE THREE FROM MONTHS ENDED MONTHS ENDED MARCH 24, 1998 SEPPTEMBER 30 SEPTEMBER 30 SEPTEMBER 30 SEPTEMBER 30 TO CASH FLOWS FROM OPERATING ACTIVITIES 2004 2003 2004 2003 SEPTEMBER 30, 2004 Net Income $ (530,687) $ (604,208) $ (161,778) $ (200,662) $ (3,696,666)  Adjustments to reconcile net income to net cash provided by operating activities Depreciation 13,902 12,162 4,774 4,054 144,510 Amortization 58,513 88,575 23,512 29,526 513,988 Increase (decrease) in: Interest Receivable 23,633 34,253 -- 35,749 (15,108) Accounts Receivable (262) 132,741 2,666 44,247 (262) Prepaid Expenses -- 11,356 -- 5,896 -- Inventory (103,740) -- 376 -- (103,740) Research and Development 3,580 (114,903) 29,780 (61,870) (513,988) Decrease (increase) in: Accounts Payable (45,210) 93,453 (31,592) 31,151 153,586 Other Comprehensive Income 1,234 3,192 (26,584) 2,474 17,711 Accrued Liabilities (18,114) 6,431 -- 2,144 -- Net Cash Provided (Used) By Operating Activities (597,151) (336,948) (158,846) (107,291) (3,499,968)  CASH FLOWS FROM INVESTING ACTIVITIES Cash Used for Deposit 7,055 6,146 -- 3,074 (234,068) Cash Used of Patent Acquisition -- -- -- -- (637,260) Acquisition of Fixed Assets (14,039) 4,208 -- 1,403 (197,198) (Increase) decrease in Marketable Securities 73,175 (40,046) 2,569 (26,697) (22,855) Net Cash (Used) By Investing Activities 66,191 (26,692) 2,569 (22,220) (1,091,381)  Loans From Shareholders 385,631 486,628 124,060 162,210 1,105,103 Sale of Common Stock -- -- -- -- 3,502,601 Net Cash (Used) By Financing Activities 385,631 486,628 124,060 162,210 4,607,705  NET INCREASE (DECREASE) IN CASH (145,239) 119,988 (32,217) 32,699 16,356  CASH AT BEGINNING OF PERIOD 161,685 12,500 48,573 99,789 --  CASH AT END OF PERIOD $ 16,356 $ 132,488 $ 16,356 $ 132,488 $ 16,356  Cash Paid for Interest -- -- -- -- 7,301


See accompanying Notes to Financial Statements.   MEDITECNIC, INC. (A Development Stage Company) NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED) SEPTEMBER 30, 2004   Item 1.       Comments  The accompanying financial statements are unaudited, but in the opinion of the management of the Company, contain all adjustments, consisting of only normal recurring accruals, necessary to present fairly the financial position at September 30, 2004, the results of operations for the three and nine months ended September 30,  2004 and 2003, and the cash flows for the nine months ended September 30, 2004 and 2003.  Reference is made to the Company's Form 10-KSB for the year ended December 31, 2003.  The results of operations for the three months ended September 30, 2004 are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2004.  Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION  The Company had no sales in the three and nine months ended September 30, 2004 and in the three and nine months ended September 30, 2003. Our net loss was $200,662 and $530,687 in the three and nine months ended September 30, 2004, compared to  $114,980 and $394,315 for the three and six months ended September 30, 2003. The increase primarily was due to increases in staff research and office rent.  The Company invests cash in marketable securities. A portion of the Companys assets are valued in currencies other than the US dollar, primarily Swiss francs. We recognize gains and losses on the currency exchange rate changes from time to time.  The Company is being funded by loans from shareholders, including  $385,631 loaned in the nine months ended September 30, 2004.  Information included in this annual report  includes forward looking statements, which can be identified by the use of forward-looking terminology such as may, expect, anticipate, believe, estimate, or continue, or the negative thereof or other variations thereon or comparable terminology. The statements in "Risk Factors" and other statements and disclaimers in this registration statement constitute cautionary statements identifying important factors, including risks and uncertainties, relating to the forward-looking statements that could cause actual results to differ materially from those reflected in the forward-looking statements.  Since we have not yet generated any revenues, we are a development stage company as that term is defined in paragraphs 8 and 9 of SFAS No. 7.   Our auditors have included an explanatory paragraph in their report on our financial statements, relating to the uncertainty of our business as a going concern, due to our lack of operating history or current revenues and competitive position.  We do not believe that conventional financing, such as bank loans, is available to us due to these factors.  We have no bank line of credit available to us.  Management believes that it will be able to raise the required funds for operations from one or more future offerings, in order to effect our business plan.  Our future operating results are subject to many facilities, including:  o     our success in developing our technology;  o     our ability to obtain customers for our devices;  o     the effects of competition;  o     our ability to obtain additional financing; and  o     other risks which we identify in future filings with the SEC.  Any or all of our forward looking statements in this annual report and in any other public statement we make may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Consequently, no forward looking statement can be guaranteed. In addition, we undertake no responsibility to update any forward-looking statement to reflect events or circumstances which occur after the date of this report.  PART II.  OTHER INFORMATION  Item 1. LEGAL PROCEEDINGS  -  None  Item 2. CHANGES IN SECURITIES - None  Item 3. DEFAULTS UPON SENIOR SECURITIES - None  Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS - None  Item 5. OTHER INFORMATION - None  Item 6. EXHIBITS --None





SIGNATURES  Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.   MEDITECNIC, INC.    Date: October 6, 2008 By:/s/ Luc Badel Luc Badel Treasurer (chief financial officer and accounting officer and duly authorized officer)